Review Article

New Insights about Congenital Infection by Human Cytomegalovirus: Unveiling the Role of PPARγ

Stephane Chavanas1,2,3,*
1Centre de Physiopathologie Toulouse Purpan, Inserm Umr 1043, Toulouse, France
2CNRS UMR 5282 Toulouse, France
3Université Paul Sabatier, Toulouse, France

Corresponding author: Stephane Chavanas, Centre de Physiopathologie Toulouse Purpan, INSERM UMR 1043, Toulouse, France, Tel: 33-0562744539; E-mail: stephane.chavanas@inserm.fr

Received date: June 22, 2016; Accepted date: July 08, 2016; Published date: July 13, 2016

Abstract

Congenital infection by human cytomegalovirus (HCMV) might result in permanent neurological sequelae, including sensorineural deafness, cerebral palsies or devastating neurodevelopmental abnormalities. Neural progenitors have been suspected to be key targets of infection, hence a number of studies have shown that HCMV is able to infect neural cells and alter their differentiation. However, little was known about the molecular and genetic bases underlying homeostatic changes in the infected progenitor. We recently disclosed that Peroxisome Proliferator-Activated Receptor gamma (PPARγ), a transcription factor of the nuclear receptor superfamily, is a key determinant of HCMV pathogenesis in the developing brain. Using neural stem cells from human embryonic stem cells, we showed that HCMV infection strongly increases levels and activity of PPARγ in NSCs. Consistently, increased PPARγ expression was found in brain section of fetuses infected by HCMV, but not in uninfected controls, what strongly supported the in vitro data. Here we review and discuss past and recent findings on the neuropathogenesis of HCMV congenital infection.

Keywords: Congenital infection; Human cytomegalovirus; HCMV; Neurotropic viruses

Introduction

Infections by neurotropic viruses in pregnancy may lead to neurodevelopmental abnormalities in the fetus. As infections by rubella, varicella zoster, or HIV to name a few, congenital infection by human cytomegalovirus (HCMV) may cause spontaneous abortion, fetal death, or neurodevelopmental abnormalities. Indeed, HCMV is the most frequent infectious cause of permanent neurological sequelae. About 1% of newborns are congenitally infected with HCMV each year [1]. Five to 10% among them show severe neurological or neurodevelopmental defects at birth, presenting with deafness, blindness, mental retardation, cerebral palsy, microcephaly, hydrocephalus... whereas 10 to 15% additional infected infants are asymptomatic at birth but subsequently develop sensorineural hearing loss, seizure or epilepsy [1]. Spastic cerebral palsies cause severe orthopaedic issues. Overall, patients with permanent sequelae represent 0.1%-0.2% of all live births, a frequency comparable to that of Down syndrome or fetal alcohol syndrome [1]. Not only HCMV congenital infection is a public health issue, it is also a key social and economic burden due to the amount of time and money needed for care and education of patients: the direct annual care costs for patients are estimated at $1-$2 billion in the USA [2]. No vaccine is available. Early neonatal antiviral treatment might provide benefit for affected newborns despite limitations due to toxicity [3]. Here we review past and recent findings on the neuropathogenesis of HCMV congenital infection.

HCMV Congenital Infection

HCMV is a BetaHerpes virus with a worldwide distribution. It is highly prevalent in the general population: seroprevalence ranges between 40% and 90%, with the greatest values among racial/ethnic minorities and persons of lower socio-economic background status [1]. HCMV is transmitted through close non-sexual or sexual contact, breastfeeding, blood transfusions, and organ transplantation [2]. For the pregnant woman, the most likely source of infection is the contact with the urine or saliva of young children, including her own children [2]. Lifelong latency is established after a primary infection. Though infection of immunocompetent adults is almost always benign, HCMV is responsible for serious illness and death in immunocompromised hosts, and is a major hazard for the fetus after infection during pregnancy. HCMV infection in utero is believed to occur through transplacental hematogenous spread [4]. Congenital HCMV disease is associated with a wide range of neurodevelopmental disabilities, including hearing and vision loss and mental retardation, as well as structural brain abnormalities including intracranial calcifications, microcephaly, hydrocephalus, ventriculomegaly, ventriculomegaly, polymicrogyria, porencephaly, and schizencephaly [5]. Neurological outcomes are more severe when infection occurs during the first trimester [5].

HCMV Tropism in the Developing Brain

HCMV is known to infect a wide spectrum of target cell types, either in parenchyma or connective tissue. Epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, hematopoietic cells are the predominant targets of HCMV [6]. Characterizing HCMV tropism in the brain is critical to understand its neuropathy. Studies in the mouse
revealed that the HCMV murine counterpart, namely murine cytomegalovirus (MCMV), infected the developing brain, and more precisely, the cerebral ventricular walls, a region known to contain neural progenitors [7]. Mouse neurons were also found to be sensitive to infection by MCMV [7].

Because such studies in human were not possible, studies were performed using primary or secondary cultures of human brain cells prepared from deceased, uninfected fetus, which were eventually infected by HCMV in vitro. These studies reported that brain microvascular endothelial cells, astrocytes, neuronal cells, oligodendroglial cells, microglia/macrophages, and neural progenitor/stem cells were sensitive to HCMV infection ex vivo [8-12]. Besides, immunohistopathological and in situ hybridization analyses of brain samples from AIDS patients infected by HCMV detected HCMV in neurons and astrocytes, oligodendrocytes, ependyma, choroid plexus, endothelia, in perianl endoneurium and in leptomeninges [13]. However, no histological study identifying the different cell types actually infected in utero during congenital HCMV infection were available, except one which reported HCMV inclusion bodies in the brain of premature infants with lethal congenital cytomegalovirus infection [14]. In our study, we explored the expression of the immediate early HCMV antigen (IE), a factor encoded by the HCMV genome and critical for virus replication, in histopathological slides from infected or non-infected fetus. We observed cells clearly immunoreactive to IE in the ependymal and germinative zones of the brain of infected cases [15]. Together these studies indicate that a variety of brain cell types are sensitive to HCMV infection, including neural stem/progenitor cells.

Noteworthy, it has been reported that the susceptibility of primary human NPCs to HCMV is retained concomitantly with differentiation into glial cells but is actively repressed following differentiation into neurons [8].

HCMV Replication in Neural Cells

Since IE expression is required, but not always sufficient to virus replication, our results did not formally show that progenitors are permissive to HCMV infection in vivo, and did not rule out the possibility of abortive replication. However, it was not possible to show actual production of infectious particles in utero from fixed samples. Therefore we investigated the permissivity of neural progenitors to HCMV in vitro, using a new disease model: human neural stem cells (NSCs) generated from embryonic stem (ES) cells. NSCs were generated through early neuroepithelial differentiation of human ES cells in a monolayer system using SMAD inhibitors and the defined medium N2B27 [16]. This method allowed for efficient neural commitment, generation of highly neuronogenic NSCs, and, as compared to progenitors prepared from deceased fetus, avoided factors as donor variability (including gestation age), and allowed for deep in vitro investigations given their high proliferative capacity and stability in culture. NSCs displayed a cortical phenotype with positive immunostaining and/or high levels of expression of polarized neural stem cells and radial glia markers, in the absence of immunoreactivity to non-cortical markers [17]. This phenotype was particularly relevant with respect to the fact that congenital HCMV infection targets cortical areas of the developing brain as well as radial glia cells [11]. We showed that NSCs supported viral replication, exhibited strong expression of early and late antigens, showed assembled viral particles (Figure 1), and allowed for efficient spreading and allowed efficient production of infectious particles in vitro [15]. This result was in agreement with other studies using progenitors from human fetal brain [8,10,12] or from iPS cells [18,19]. Importantly, infected NSCs or progenitors remained immunoreactive to the stemness markers nestin, SOX2 [15] and A2B25 [8], suggesting that infection did not cause detectable changes in their stem cell status. It is worth noting however that permissivity seems to be dependent upon the differentiation status of the neural progenitor, as shown by a recent study [20]. More experiments are needed to investigate the molecular networks underlying the relation between permissivity and differentiation status of the host NSC. Such a connection has been already reported in ES cells [21,22] or the hematopoietic lineage [23].

Apart from progenitors, permissivity of neurons and astrocytes to HCMV has been investigated in vitro. Convergent studies showed that primary human astrocytes as well as astrocytes generated in vitro from human neural progenitors support highly productive, cytopathic replication of CMV [9,24,25]. In contrast, studies on neuron permissivity lead to conflicting results. Primary mature human neurons showed no viral antigen expression or cytopathic effect following infection in vitro [9], whereas neurons derived from human neural progenitors prepared from fetus were reported to be permissive [10,25] or not [8] to HCMV infection.

PPARγ: A Key Transcription Factor in Pathogenesis of HCMV Congenital Infection

HCMV infection alters the levels and/or activity of various host transcription factors of the host cell [26]. Notably, some host factors such as NF-κB [27] are used by HCMV for its own replication, through their recruitment on cognate DNA segments within HCMV Major Immediate Early Promoter (MIEP). Likewise, we showed that Peroxisome Proliferator-Activated Receptor gamma (PPARγ) is activated during HCMV infection of placenta cells, and is required for efficient virus replication [28]. PPARγ is a ligand-dependent transcription factor, member of the nuclear receptor superfamily, which plays key roles in regulating cellular function and tissue homeostasis [29]. Notably, PPARγ was thought to play a role in brain

---

Figure 1: Transmission electron microscopy show morphologically normal (white arrowheads) or abnormal (black arrowheads) viral particles within the cytoplasm of an infected NSC. M: mitochondria. Scale bar: 0.5 µm.
Lipid Metabolism and HCMV Infection

We investigated the mechanisms of PPARγ activation in NSCs. We found that levels of 9-hydroxyoctadecadienoic acid (9-HODE) were significantly increased in infected NSCs. 9-HODE is a polyunsaturated fatty acid (PUFA) known to be an activating ligand of PPARγ. Notably, other PUFAs, namely 13-HODE and 15-hydroxyeicosatetraenoic acid (15-HETE) activate PPARγ in human cytrophoblast cells and placenta histocultures infected by HCMV [32]. Also, it has been shown that HCMV infection of fibroblasts caused increased biosynthesis of prostaglandin E2 (PGE2), and that PGE2 was required for efficient viral replication [33]. Noteworthy, PGE2 is also a PPARγ activating ligand. Together these studies underscored the importance of lipid metabolism in PPARγ activation in cells infected by HCMV, and, notably, the role of HCMV “onboarded” cPLA2 (oPLA2). oPLA2 is a cell-derived cPLA2, packaged in the tegument of the viral particle during release of HCMV from the infected cell [34]. oPLA2 is required for infectivity in human fibroblasts [34], placenta trophoblast cells [32] and NSCs [15]. Indeed, oPLA2 catalyzes the release of linoleic acid (LA) or arachidonic acid (AA) from host membrane phospholipids (PL) upon infection. LA oxidation driven by 15-lipoxygenase (15-LOX) generates 9-HODE and 13-HODE, whereas AA oxidation driven by 15-LOX or COX-2 generates 15-HETE or PGE2, respectively. In short, HCMV particles carry in their tegument oPLA2 as an “ignition factor” for synthesis of PPARγ activating ligands, which, in turn, will favor viral replication (Figure 2).

Figure 2: Proposed hypothetical model for PPARγ activation by HCMV infection in NSC. HCMV particle release onboarded cPLA2 (oPLA2) which catalyzes linoleic acid (LA) release from membrane phospholipids (PL). Cell lipoxygenase (LOX) converts LA into 9-HODE, which activates PPARγ (Py). Activated PPARγ translocates to the nucleus where it regulates host and viral gene expression. As a result, PPARγ activity enhances viral replication and inhibits neuronogenic differentiation.

Primary HCMV infection is followed by a lifelong persistence of the virus in a latent state, namely latency, and reactivation may occur later in life. NSCs may help investigating if HCMV reactivation from latently infected brain cells might occur and be deleterious. Noteworthy, it has been reported that murine cytomegalovirus is able to establish latency and reactivate in mouse brain slice histocultures [7]. Last, NSCs may probably be extended to other viral pathologies of the central nervous system such as Zika virus (ZIKV) congenital infection.

Conclusion

Activation of PPARγ by HCMV infection illustrates that hijacking of host nuclear factors by the virus may have devastating outcomes on the host development. Our findings disclosed that PPARγ play a critical role in the neurodevelopmental sequelae of HCMV congenital infection. NSCs turned out to be a relevant tool for modeling functional correlates of HCMV infection. Such a cell platform will allow characterization of PPARγ gene targets in the infected cell, and thereby identify new pathogenic effectors of HCMV infection in the developing brain.

References


